Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessBiogen Shares Drop 5 percent Despite Q2 Beat

Biogen Shares Drop 5 percent Despite Q2 Beat

Add to Favorite
Added to Favorite


Biogen Inc. (NASDAQ:BIIB) shares closed more than 5% lower on Wednesday despite the company’s reported strong Q2 results, with EPS of $5.25 coming in better than the Street estimate of $4.13. Revenue was $2.59 billion, compared to the Street estimate of $2.49 billion.
The company expects the full 2022-year EPS to be in the range of $15.25-$16.75, compared to the Street estimate of $15.54. Full-year revenue is expected to be in the range of $9.9-10.1 billion, compared to the Street estimate of $9.84 billion.
According to Wedbush analysts, generic competition remains an issue on the commercial front, however, FX headwinds are now also present with management noting a negative impact on 2022 revenue of approximately $55 million. The company reported that the BIIB104 program in CIAS will be terminated after failing to meet its endpoints. The company’s R&D prioritization continues but would seemingly need lecanemab Phase 3 CLARITY AD results (expected Fall 2022) before the process can conclude.
The analysts continue to see the company in a holding pattern and while the commercial results are better than anticipated, they view it as a declining business.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Wheaton Precious Metals Corp. (NYSE:WPM) Financial Overview

Earnings Per Share (EPS) for Q3 2024 stood at...

NRG Energy, Inc. (NYSE:NRG) Stock Price Target Shows Positive Trend

The consensus price target for NRG Energy, Inc. (NYSE:NRG)...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Overview

The consensus price target for Xeris Biopharma's stock has...